AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$NBIX

BENEVICH ERIC sold $333K of NBIX

BENEVICH ERIC (Chief Commercial Officer) sold 2,154 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $154.61 ($0.33M total) on 2026-09-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BENEVICH ERIC
Published Sep 11, 2026, 12:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 12:54 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NBIX
Neutral
high confidence
Mentioned
$NBIX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NBIXNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move NBIX price materially.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate developments not disclosed.

Relevance 3/10Novelty 4/10Timing: filed Sep 10, 2026

Background

Form 4 filings disclose insider trades; a 10b5-1 plan sale is pre‑arranged and often viewed as neutral.

Company-level read

Ticker impact

$NBIXNeutralHigh confidence
Context

Chief Commercial Officer Eric Benezich sold 2,154 shares for $333K via a 10b5-1 plan, reducing his stake to 64,408 shares.

Expected impact

Potential slight downward pressure, but likely negligible.

Evidence & confidence

The sale size is modest relative to market cap and follows a pre‑arranged plan, indicating no urgent market signal.

Market effects

Sector

No broader sector impact; typical insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Company
    Neurocrine Biosciences Inc.

    Biotech firm (ticker NBIX) subject of the insider sale.

  • Executive
    Eric Benezich

    Chief Commercial Officer of Neurocrine Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NBIX insider trading history →

Related articles

$NBIXHighAI 8/10

NBIX Stock Jumps As Earnings Smash Estimates And Pipeline Expands

Neurocrine Biosciences Inc. (NBIX) stock rose 14.3% after strong Q3 earnings, with revenue of $1.12B (up from $794.9M YoY) and adjusted EPS of $3.29 (up from $2.17). The company also reported positive clinical data and expanded its pipeline, including a new Phase 2 trial for Alzheimer's treatment. Management raised FY26 revenue guidance to $2.9B–$2.925B, below consensus of $3.9B.

timothysykes.com
$NBIXHighAI 9/10

Why is Neurocrine Biosciences stock surging today?

Neurocrine Biosciences (NBIX) stock rose 15.1% after reporting Q3 adjusted earnings of $3.29 per share, beating estimates by 72%, and revenue of $1.12 billion, up 41% YoY. The company surpassed $1 billion in net product sales for the first time, driven by its top products. Analysts raised price targets, with Baird setting a $225 target. Management increased 2026 INGREZZA sales guidance to $2.9-$2.925 billion.

investing.com
$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com